MedPath

A study evaluating the safety of dose-dense EC with pegfilgrastim.

Phase 2
Conditions
breast cancer
Registration Number
JPRN-UMIN000020834
Lead Sponsor
Fukuyama city hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1 allergic for G-CSF 2 a case of active infection 3 pregnancy or breast-feeding 4 severe comobidity

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rate of severe adverse event
Secondary Outcome Measures
NameTimeMethod
rate of febrile neutropenia, oher adverse event
© Copyright 2025. All Rights Reserved by MedPath